Search
Balsalazide
go.drugbank.com/drugs/DB01014ApprovedBalsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK.
Synonyms: (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acidChloramphenicol succinate
go.drugbank.com/drugs/DB07565ApprovedChloramphenicol succinate is an ester prodrug of [chloramphenicol].[A192987] Chloramphenicol is a bacteriostatic antibiotic.
Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic IndexH3B-8800
go.drugbank.com/drugs/DB14017InvestigationalH3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551].
CRx-139
go.drugbank.com/drugs/DB05744ExperimentalThis novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously.
XP12B
go.drugbank.com/drugs/DB04928InvestigationalXP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.
Danoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAmprenavir
go.drugbank.com/drugs/DB00701ApprovedWithdrawnAmprenavir is a protease inhibitor used to treat HIV infection.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseMuraglitazar
go.drugbank.com/drugs/DB06510InvestigationalMuraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesDP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.